In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Immune Design Corp.

www.immunedesign.com

Latest From Immune Design Corp.

Merck Strengthening Vaccine Capabilities By Acquiring Troubled Immune Design

Recently battered by clinical setbacks, Immune Design has a co-development partnership with Merck around Keytruda and Merck’s Perlmutter is a former board member. Merck would pay roughly $300m to acquire the company and its immune system-boosting technologies.

Deals ImmunoOncology

Oxford BioMedica CEO To Hire More People, Expects More Deals Following Gene Therapy Pact With Axovant

Britain's Oxford BioMedica has signed a $842m deal with US-based Axovant Sciences to commercialize its next generation gene therapy for Parkinson's disease.

Deals Regenerative Medicine

Pipeline Watch: Phase III Starts With Oxabact, Imeglimin And Favipiravir

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

 

Pipeline Watch Approvals

Pipeline Watch: Phase III Readouts For Talazoparib, Ampion, Avatrombopag

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Infectious & Viral Diseases
  • Alias(es)
  • Vaccsys Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Immune Design Corp.
  • Senior Management
  • Carlos V Paya, MD, PhD, Pres. & CEO
    Stephen R Brady, EVP, Fin. & Strategy
    Jan Henrik ter Meulen, MD, CSO
    Sergey Yurasov, MD, PhD, SVP, Clinical Dev. & CMO
  • Contact Info
  • Immune Design Corp.
    Phone: (206) 682-0645
    1616 Eastlake Ave. E., Ste. 310
    Seattle, WA 98102
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register